Technical Analysis for RETA - Reata Pharmaceuticals, Inc. - Class A

Grade Last Price % Change Price Change
D 122.26 -0.75% -0.93
RETA closed down 0.75 percent on Friday, February 26, 2021, on 74 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to find support at its 50 day moving average.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down
Historical RETA trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
NR7 Range Contraction 0.00%
Multiple of Ten Bullish Other 0.00%
200 DMA Resistance Bearish -0.75%
Multiple of Ten Bearish Other -0.75%
50 DMA Support Bullish -3.21%
Multiple of Ten Bullish Other -3.21%
20 DMA Support Bullish 0.97%
Crossed Above 50 DMA Bullish 0.97%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.97%
Older End-of-Day Signals for RETA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Trending on StockTwits about 14 hours ago
Trending on StockTwits about 16 hours ago
50 DMA Support 3 days ago
Down 3% 3 days ago
10 DMA Resistance 3 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Reata Pharmaceuticals, Inc. - Class A Description

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company focuses on drugs with novel mechanisms of action that modulate regulatory proteins called transcription factors. Its lead product candidates include bardoxolone methyl and RTA 408, which are members of a class of small molecules called antioxidant inflammation modulators. It is involved in LARIAT, a Phase II study of bardoxolone methyl for the treatment of pulmonary arterial hypertension and pulmonary hypertension due to interstitial lung disease. RTA 408 is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia and mitochondrial myopathies. Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biology Diseases Clinical Development Inflammation Health Care Hypertension Pulmonary Arterial Hypertension Transcription Myopathy Antioxidant Pulmonary Hypertension Oxidative Stress Transcription Factors Transcription Factor Mitochondria Ataxia Friedreich's Ataxia Interstitial Lung Disease

Is RETA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 209.91
52 Week Low 88.17
Average Volume 285,038
200-Day Moving Average 130.45
50-Day Moving Average 119.06
20-Day Moving Average 118.41
10-Day Moving Average 123.33
Average True Range 7.12
ADX 12.6
+DI 22.91
-DI 23.35
Chandelier Exit (Long, 3 ATRs ) 110.09
Chandelier Exit (Short, 3 ATRs ) 122.09
Upper Bollinger Band 132.15
Lower Bollinger Band 104.68
Percent B (%b) 0.64
BandWidth 23.20
MACD Line 1.51
MACD Signal Line 0.87
MACD Histogram 0.6441
Fundamentals Value
Market Cap 3.55 Billion
Num Shares 29.1 Million
EPS -4.06
Price-to-Earnings (P/E) Ratio -30.14
Price-to-Sales 589.00
Price-to-Book 27.68
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 131.52
Resistance 3 (R3) 131.44 128.26 129.98
Resistance 2 (R2) 128.26 125.90 128.31 129.46
Resistance 1 (R1) 125.26 124.45 123.68 125.35 128.95
Pivot Point 122.09 122.09 121.30 122.13 122.09
Support 1 (S1) 119.09 119.73 117.50 119.17 115.57
Support 2 (S2) 115.91 118.27 115.96 115.06
Support 3 (S3) 112.91 115.91 114.54
Support 4 (S4) 113.00